Page last updated: 2024-08-26

sr141716 and Cardiovascular Diseases

sr141716 has been researched along with Cardiovascular Diseases in 71 studies

Research

Studies (71)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	64 (90.14)	29.6817
2010's	7 (9.86)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Kintscher, U	1
Chatterjee, T; Ince, H; Nienaber, ChA; Rehders, TC; Ritz, A	1
Di Marzo, V	1
Deedwania, P	1
Rapezzi, C; Volpe, M	1
Manzato, E; Marchiori, M; Zambon, A	1
Golay, A	1
Chou, CM; Samaha, FF	1
Höcht, C; Mayer, MA; Puyó, A; Taira, CA	1
Després, JP	2
Golay, A; Vincent, M	1
Paquot, N; Scheen, AJ	1
Kew, ST; Loh, KY	1
Rosenson, RS	1
Boekholdt, SM; Peters, RJ	1
Bhatt, DL; Bousser, MG; Cohen, E; Creager, MA; Despres, JP; Easton, JD; Fox, KA; Gaudin, C; Hamm, CW; Job, B; Montalescot, G; Murphy, JH; Pearson, TA; Steg, PG; Topol, EJ	1
Lachat, C; Lucet, C; Roberfroid, D	1
Kwatra, SG	1
Madsbad, S	1
Acharya, A; Balaraman, R; Chatterjee, A; Jain, MR; Mohapatra, J; Pandya, G; Sharma, M	1
Boesten, JE; Kaper, J; Kroon, AA; Stoffers, HE; van Schayck, OC	1
Böcking, W; Bramlage, P; Kirch, W	1
Bérubé-Parent, S; Chaput, JP; Tremblay, A	1
Schaerlig, E	1
Cox, SL	1
Letonturier, P	1
Cannon, CP	1
Nesto, RW	1
Aronne, LJ; Devin, J; Heshmati, HM; Pi-Sunyer, FX; Rosenstock, J	1
Tonstad, S	1
Majumdar, S; Padwal, R	1
Esposito, K; Giugliano, D	1
Alméras, N; Després, JP; Lemieux, I	1
Boyd, ST; Fremming, BA	1
Cannon, CP; Gelfand, EV	1
Behn, A; Ur, E	1
Sulcová, A	1
Caterson, ID; Finer, N	1
Wierzbicki, AS	1
Connell, JM; Ritchie, SA	1
Fujioka, K	1
Stiefelhagen, P	1
Hollander, P	1
Bray, G; Hadley, RD; Henry, RR; Lillo, JL; Woods, SC	1
Athyros, VG; Kakafika, AI; Karagiannis, A; Mikhailidis, DP	1
Pipe, AL; Quinlan, B; Reid, RD; Riley, DL	1
Bloch, MJ; Bronander, KA	1
Ashton, JC; Smith, PF	1
Anthenelli, RM	1
Giusti, V	1
Jensen, MD	1
Lillo, JL	1
Saavedra, LE	1
Watson, KE	1
Van Gaal, L	1
Böcking, W; Bramlage, CP; Bramlage, P; Kirch, W; Schindler, C; Thoenes, M	1
Bodary, PF; Eitzman, DT; Iglay, HB	1
Aronne, LJ; Isoldi, KK	2
Cannon, CP; Steinberg, BA	1
Boekholdt, SM; Jukema, JW; Peters, RJ	1
Cohen, AF; Dubois, EA; Pijl, H; van Bronswijk, H	1
Després, JP; McCarthy, C; Pi-Sunyer, X; Scheen, A; Van Gaal, L	1
Nilsson, PM	1
Aronne, LJ; Dikkers, C; Wright, SM	1
Hanotin, C; Rissanen, AM; Rössner, S; Scheen, AJ; Van Gaal, LF; Ziegler, O	1
Scheen, AJ	1
Bonner, TI; Goparaju, SK; Járai, Z; Kunos, G; Razdan, RK; Sugiura, T; Wagner, JA; Wang, L; Zimmer, A; Zimmer, AM	1

Reviews

40 review(s) available for sr141716 and Cardiovascular Diseases

Article	Year
The endocannabinoid system and cardiometabolic risk: effects of CB1 receptor blockade on lipid metabolism. International journal of cardiology, 2009, Jan-24, Volume: 131, Issue:3 Topics: Cannabinoid Receptor Modulators; Cardiovascular Diseases; Dyslipidemias; Endocannabinoids; Humans; Insulin Resistance; Lipid Metabolism; Obesity; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Rimonabant; Risk Factors; Signal Transduction	2009
Blockade of the endocannabinoid system for the reduction of cardiometabolic risk factors. Obesity (Silver Spring, Md.), 2009, Volume: 17, Issue:2 Topics: Animals; Cannabinoid Receptor Modulators; Cardiovascular Diseases; Disease Models, Animal; Endocannabinoids; Energy Metabolism; Humans; Mice; Obesity; Piperidines; Pyrazoles; Rats; Rimonabant; Risk Factors	2009
Recent advances in obesity pharmacotherapy. Current clinical pharmacology, 2009, Volume: 4, Issue:1 Topics: Animals; Anti-Obesity Agents; Cardiovascular Diseases; Cyclobutanes; Humans; Lactones; Obesity; Orlistat; Piperidines; Pyrazoles; Rimonabant	2009
Pleiotropic effects of rimonabant: clinical implications. Current pharmaceutical design, 2009, Volume: 15, Issue:5 Topics: Abdominal Fat; Animals; Anti-Obesity Agents; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Humans; Obesity; Piperidines; Pyrazoles; Randomized Controlled Trials as Topic; Rimonabant; Risk Factors	2009
Use of cannabinoid CB1 receptor antagonists for the treatment of metabolic disorders. Best practice & research. Clinical endocrinology & metabolism, 2009, Volume: 23, Issue:1 Topics: Atherosclerosis; Blood Glucose; Cannabinoid Receptor Modulators; Cardiovascular Diseases; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Fasting; Glucose; Glycated Hemoglobin; Humans; Lipid Metabolism; Metabolic Diseases; Obesity; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Rimonabant; Risk Factors	2009
Endocannabinoid system and cardio-metabolic risk. The Medical journal of Malaysia, 2008, Volume: 63, Issue:4 Topics: Animals; Cannabinoid Receptor Modulators; Cardiovascular Diseases; Endocannabinoids; Humans; Metabolic Syndrome; Obesity; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Rimonabant	2008
Role of the endocannabinoid system in abdominal obesity and the implications for cardiovascular risk. Cardiology, 2009, Volume: 114, Issue:3 Topics: Animals; Cannabinoid Receptor Modulators; Cardiovascular Diseases; Clinical Trials as Topic; Endocannabinoids; Humans; Mental Disorders; Obesity, Abdominal; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Rimonabant; Risk Factors	2009
Obesity and cardiovascular physiology: impact of some pharmacological agents. Current vascular pharmacology, 2005, Volume: 3, Issue:2 Topics: Animals; Anti-Obesity Agents; Appetite Depressants; Cardiovascular Diseases; Cardiovascular Physiological Phenomena; Clinical Trials as Topic; Cyclobutanes; Humans; Lactones; Obesity; Orlistat; Piperidines; Pyrazoles; Rimonabant; Risk Factors	2005
Rimonabant hydrochloride: an investigational agent for the management of cardiovascular risk factors. Drugs of today (Barcelona, Spain : 1998), 2005, Volume: 41, Issue:8 Topics: Animals; Cardiovascular Diseases; Humans; Metabolic Syndrome; Obesity; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Rimonabant; Risk Factors; Smoking Cessation	2005
The endocannabinoid system: a new approach to control cardiovascular disease. Clinical cornerstone, 2005, Volume: 7, Issue:2-3 Topics: Appetite Regulation; Cannabinoid Receptor Modulators; Cardiovascular Diseases; Endocannabinoids; History, 20th Century; Humans; Intra-Abdominal Fat; Metabolic Syndrome; Obesity; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Rimonabant	2005
Managing cardiovascular risk inpatients with metabolic syndrome. Clinical cornerstone, 2005, Volume: 7, Issue:2-3 Topics: Cardiovascular Diseases; Exercise; Feeding Behavior; Humans; Metabolic Syndrome; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Rimonabant; Risk Assessment; Risk Factors	2005
Rimonabant: a cannabinoid receptor blocker for the treatment of metabolic and cardiovascular risk factors. Nutrition, metabolism, and cardiovascular diseases : NMCD, 2006, Volume: 16, Issue:2 Topics: Cannabinoid Receptor Antagonists; Cardiovascular Diseases; Clinical Trials, Phase III as Topic; Diabetes Mellitus, Type 2; Humans; Hyperlipidemias; Metabolic Syndrome; Obesity; Piperidines; Pyrazoles; Rimonabant; Risk Factors; Smoking Cessation; Tobacco Use Disorder; Treatment Outcome; Weight Gain	2006
Contribution of CB1 blockade to the management of high-risk abdominal obesity. International journal of obesity (2005), 2006, Volume: 30 Suppl 1 Topics: Abdominal Fat; Adiponectin; Animals; Appetite Regulation; Cardiovascular Diseases; Energy Metabolism; Humans; Obesity; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Rimonabant; Risk Factors	2006
Rimonabant: a cannabinoid receptor type 1 blocker for management of multiple cardiometabolic risk factors. Journal of the American College of Cardiology, 2006, May-16, Volume: 47, Issue:10 Topics: Animals; Atherosclerosis; Blood Glucose; Cannabinoid Receptor Modulators; Cardiovascular Diseases; Cardiovascular System; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Humans; Lipid Metabolism; Marijuana Abuse; Metabolic Syndrome; Obesity; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Rimonabant; Smoking Cessation	2006
The obesity epidemic and its cardiovascular consequences. Current opinion in cardiology, 2006, Volume: 21, Issue:4 Topics: Appetite Depressants; Body Fat Distribution; Body Mass Index; Cardiovascular Diseases; Cyclobutanes; Humans; Inflammation; Insulin Resistance; Intra-Abdominal Fat; Lactones; Life Style; Lipid Metabolism; Metabolic Syndrome; Obesity; Orlistat; Piperidines; Pyrazoles; Rimonabant; Thiazolidinediones; Waist-Hip Ratio	2006
[Impact of endocannabinoid system in modulation of cardiometabolic risk factors]. Vnitrni lekarstvi, 2006, Volume: 52, Issue:6 Topics: Cannabinoid Receptor Antagonists; Cannabinoid Receptor Modulators; Cardiovascular Diseases; Endocannabinoids; Humans; Lipid Metabolism; Piperidines; Pyrazoles; Receptors, Cannabinoid; Rimonabant; Risk Factors	2006
Emerging pharmacotherapy for treating obesity and associated cardiometabolic risk. Asia Pacific journal of clinical nutrition, 2006, Volume: 15 Suppl Topics: Anti-Obesity Agents; Cardiovascular Diseases; Cyclobutanes; Humans; Lactones; Obesity; Orlistat; Piperidines; Pyrazoles; Rimonabant; Risk Factors; Safety; Treatment Outcome	2006
Rimonabant: endocannabinoid inhibition for the metabolic syndrome. International journal of clinical practice, 2006, Volume: 60, Issue:12 Topics: Cannabinoid Receptor Modulators; Cardiovascular Diseases; Endocannabinoids; Humans; Metabolic Syndrome; Obesity; Piperidines; Pyrazoles; Receptors, Cannabinoid; Rimonabant; Risk Factors; Smoking Cessation	2006
The link between abdominal obesity, metabolic syndrome and cardiovascular disease. Nutrition, metabolism, and cardiovascular diseases : NMCD, 2007, Volume: 17, Issue:4 Topics: Cardiovascular Diseases; Fatty Acids, Nonesterified; Humans; Inflammation; Insulin Resistance; Interleukin-6; Intra-Abdominal Fat; Metabolic Syndrome; Obesity; Piperidines; Pyrazoles; Rimonabant; Risk Factors; Tumor Necrosis Factor-alpha	2007
Metabolic syndrome treatment strategies. Pharmacotherapy, 2006, Volume: 26, Issue:12 Pt 2 Topics: Appetite Depressants; Cardiovascular Diseases; Cyclobutanes; Exercise; Humans; Metabolic Syndrome; Obesity; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Rimonabant; Risk Factors; Weight Loss	2006
The role of endocannabinoid system blockade in the treatment of the metabolic syndrome. Journal of clinical pharmacology, 2007, Volume: 47, Issue:5 Topics: Cardiovascular Diseases; Humans; Metabolic Syndrome; Obesity; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Rimonabant; Risk Factors	2007
Smoking cessation: lessons learned from clinical trial evidence. Current opinion in cardiology, 2007, Volume: 22, Issue:4 Topics: Benzazepines; Bupropion; Cardiovascular Diseases; Clinical Trials as Topic; Dopamine Uptake Inhibitors; Humans; Nicotinic Agonists; Piperidines; Pyrazoles; Quinoxalines; Rimonabant; Smoking; Smoking Cessation; Smoking Prevention; Varenicline	2007
Potential role of the endocannabinoid receptor antagonist rimonabant in the management of cardiometabolic risk: a narrative review of available data. Vascular health and risk management, 2007, Volume: 3, Issue:2 Topics: Animals; Cardiovascular Diseases; Diabetes Mellitus; Humans; Metabolic Syndrome; Obesity; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Rimonabant; Treatment Outcome	2007
Less weight or more hype with rimonabant? Drug and therapeutics bulletin, 2007, Volume: 45, Issue:6 Topics: Anti-Obesity Agents; Cardiovascular Diseases; Drug Costs; Humans; Obesity; Piperidines; Pyrazoles; Rimonabant; Risk Factors; Treatment Outcome; Weight Loss	2007
Cannabinoids and cardiovascular disease: the outlook for clinical treatments. Current vascular pharmacology, 2007, Volume: 5, Issue:3 Topics: Animals; Anti-Obesity Agents; Cannabinoid Receptor Modulators; Cannabinoids; Cardiovascular Agents; Cardiovascular Diseases; Cardiovascular System; Humans; Obesity; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Receptor, Cannabinoid, CB2; Rimonabant; Risk Factors; Treatment Outcome	2007
Cardiovascular disease under the influence of excess visceral fat. Critical pathways in cardiology, 2007, Volume: 6, Issue:2 Topics: Adiponectin; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Humans; Intra-Abdominal Fat; Metabolic Syndrome; Obesity; Piperidines; Prospective Studies; Pyrazoles; Rimonabant; Risk Factors	2007
What is the potential role of cannabinoid-1 receptor blockade in glucose and lipid management? The American journal of medicine, 2007, Volume: 120, Issue:9 Suppl 1 Topics: Body Weight; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Drug Evaluation; Female; Humans; Male; Middle Aged; Obesity; Piperidines; Pyrazoles; Rimonabant; Risk Factors; Treatment Outcome; Waist-Hip Ratio	2007
The endocannabinoid system as a novel approach for managing obesity. The Journal of the American Osteopathic Association, 2007, Volume: 107, Issue:4 Suppl 2 Topics: Abdominal Fat; Cannabinoid Receptor Modulators; Cardiovascular Diseases; Controlled Clinical Trials as Topic; Endocannabinoids; Energy Metabolism; Homeostasis; Humans; Obesity; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Rimonabant; Risk Factors	2007
Endocannabinoid system and cardiometabolic risk. Clinical pharmacology and therapeutics, 2007, Volume: 82, Issue:5 Topics: Abdominal Fat; Adipokines; Animals; Cannabinoid Receptor Modulators; Cardiovascular Diseases; Diabetes Complications; Diabetes Mellitus; Endocannabinoids; Humans; Insulin Resistance; Lipids; Obesity; Overweight; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Rimonabant; Weight Loss	2007
Novel therapies for cardiometabolic risk reduction and implications for clinical practice. Reviews in cardiovascular medicine, 2007, Volume: 8 Suppl 4 Topics: Anti-Obesity Agents; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diet; Dyslipidemias; Exercise; Humans; Insulin Resistance; Life Style; Lipids; Metabolic Syndrome; Obesity; Piperidines; Pyrazoles; Rimonabant; Risk Assessment; Risk Factors; Treatment Outcome; Weight Loss	2007
Reducing cardiometabolic risk through selective antagonism of CB1 receptors. Clinical cornerstone, 2007, Volume: 8 Suppl 6 Topics: Cannabinoid Receptor Antagonists; Cardiovascular Diseases; Humans; Metabolic Syndrome; Obesity; Piperidines; Pyrazoles; Receptors, Cannabinoid; Rimonabant; Risk Assessment; Risk Factors	2007
[Prevention of cardiovascular disease by blocking the endocannabinoid system]. Herz, 2007, Volume: 32, Issue:7 Topics: Cannabinoids; Cardiovascular Diseases; Clinical Trials as Topic; Humans; Piperidines; Prevalence; Pyrazoles; Rimonabant; Treatment Outcome	2007
Strategies to reduce vascular risk associated with obesity. Current vascular pharmacology, 2007, Volume: 5, Issue:4 Topics: Adiponectin; Anti-Obesity Agents; Cardiovascular Diseases; Cyclobutanes; Diabetes Mellitus, Type 2; Humans; Hyperlipidemias; Hypertension; Lactones; Obesity; Orlistat; Piperidines; Pyrazoles; Rimonabant; Risk Factors	2007
Cannabinoid-1 receptor blockade in cardiometabolic risk reduction: efficacy. The American journal of cardiology, 2007, Dec-17, Volume: 100, Issue:12A Topics: Cardiovascular Diseases; Humans; Obesity; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Rimonabant; Risk Factors; Treatment Outcome	2007
Cannabinoid-1 receptor blockade in cardiometabolic risk reduction: safety, tolerability, and therapeutic potential. The American journal of cardiology, 2007, Dec-17, Volume: 100, Issue:12A Topics: Cardiovascular Diseases; Drug Tolerance; Humans; Obesity; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Rimonabant; Risk Factors; Treatment Outcome	2007
[The endocannabinoid system, overweight, and the CB1-endocannabinoid-receptor antagonist rimonabant]. Nederlands tijdschrift voor geneeskunde, 2007, Nov-24, Volume: 151, Issue:47 Topics: Cardiovascular Diseases; Depression; Diet, Reducing; Humans; Lipids; Obesity; Obesity, Morbid; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Rimonabant; Weight Loss	2007
Is weight loss beneficial for reduction of morbidity and mortality? What is the controversy about? Diabetes care, 2008, Volume: 31 Suppl 2 Topics: Bariatric Surgery; Cannabinoids; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Humans; Life Style; Multicenter Studies as Topic; Obesity; Piperidines; Power, Psychological; Pyrazoles; Rimonabant; Self Concept; Weight Loss	2008
Rimonabant: new data and emerging experience. Current atherosclerosis reports, 2008, Volume: 10, Issue:1 Topics: Adipose Tissue; Animals; Cannabinoid Receptor Antagonists; Cannabinoid Receptor Modulators; Cardiovascular Diseases; Cholesterol, HDL; Humans; Obesity; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Rimonabant; Risk Factors	2008
CB1 receptor blockade and its impact on cardiometabolic risk factors: overview of the RIO programme with rimonabant. Journal of neuroendocrinology, 2008, Volume: 20 Suppl 1 Topics: Algorithms; Anti-Obesity Agents; Cardiovascular Diseases; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Metabolic Syndrome; Metformin; Obesity; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Rimonabant; Risk Factors; Treatment Outcome	2008
Overweight and obesity: key components of cardiometabolic risk. Clinical cornerstone, 2007, Volume: 8, Issue:3 Topics: Adipocytes; Adipokines; Cardiovascular Diseases; Humans; Inflammation; Life Style; Obesity; Overweight; Piperidines; Pyrazoles; Rimonabant; Risk Assessment; Risk Factors; United States	2007

Trials

5 trial(s) available for sr141716 and Cardiovascular Diseases

Article	Year
Rimonabant for prevention of cardiovascular events (CRESCENDO): a randomised, multicentre, placebo-controlled trial. Lancet (London, England), 2010, Aug-14, Volume: 376, Issue:9740 Topics: Aged; Aged, 80 and over; Cannabinoid Receptor Antagonists; Cardiovascular Diseases; Double-Blind Method; Drug Approval; Female; Gastrointestinal Diseases; Humans; Male; Mental Disorders; Obesity; Piperidines; Pyrazoles; Rimonabant; Suicide	2010
Rimonabant improves obesity but not the overall cardiovascular risk and quality of life; results from CARDIO-REDUSE (CArdiometabolic Risk reDuctIOn by Rimonabant: the Effectiveness in Daily practice and its USE). Family practice, 2012, Volume: 29, Issue:5 Topics: Adolescent; Adult; Aged; Anti-Obesity Agents; Cardiovascular Diseases; Counseling; Double-Blind Method; Female; Humans; Male; Middle Aged; Obesity; Outcome Assessment, Health Care; Piperidines; Primary Health Care; Pyrazoles; Quality of Life; Rimonabant; Risk Reduction Behavior; Safety-Based Drug Withdrawals; United Kingdom; Waist Circumference; Young Adult	2012
Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial. JAMA, 2006, Feb-15, Volume: 295, Issue:7 Topics: Adult; Aged; Anti-Obesity Agents; Blood Pressure; Cannabinoid Receptor Antagonists; Cardiovascular Diseases; Cholesterol, HDL; Diet, Reducing; Double-Blind Method; Female; Humans; Male; Metabolic Syndrome; Middle Aged; Obesity; Overweight; Piperidines; Pyrazoles; Rimonabant; Risk Factors; Weight Loss	2006
Endocannabinoid blockade for improving glycemic control and lipids in patients with type 2 diabetes mellitus. The American journal of medicine, 2007, Volume: 120, Issue:2 Suppl 1 Topics: Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Humans; Lipid Metabolism; Male; Metabolic Syndrome; Middle Aged; Obesity; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Rimonabant; Risk Factors; Treatment Outcome	2007
Long-term effect of CB1 blockade with rimonabant on cardiometabolic risk factors: two year results from the RIO-Europe Study. European heart journal, 2008, Volume: 29, Issue:14 Topics: Adult; Anti-Obesity Agents; Blood Glucose; Body Mass Index; Cannabinoid Receptor Antagonists; Cardiovascular Diseases; Cholesterol, HDL; Dose-Response Relationship, Drug; Epidemiologic Methods; Female; Humans; Insulin; Male; Metabolic Syndrome; Middle Aged; Obesity; Piperidines; Pyrazoles; Rimonabant; Treatment Outcome; Triglycerides; Weight Loss	2008

Other Studies

26 other study(ies) available for sr141716 and Cardiovascular Diseases

Article	Year
The cardiometabolic drug rimonabant: after 2 years of RIO-Europe and STRADIVARIUS. European heart journal, 2008, Volume: 29, Issue:14 Topics: Anti-Obesity Agents; Cannabinoid Receptor Antagonists; Cardiovascular Diseases; Humans; Obesity; Piperidines; Pyrazoles; Randomized Controlled Trials as Topic; Rimonabant	2008
[Positive influence on cardiovascular risk factor by blocking the endocannabinoid system]. Praxis, 2008, May-28, Volume: 97, Issue:11 Topics: Cannabinoid Receptor Antagonists; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Humans; Metabolic Syndrome; Obesity; Piperidines; Pyrazoles; Randomized Controlled Trials as Topic; Rimonabant	2008
Play an ADAGIO with a STRADIVARIUS: the right patient for CB1 receptor antagonists? Nature clinical practice. Cardiovascular medicine, 2008, Volume: 5, Issue:10 Topics: Anti-Obesity Agents; Cardiovascular Diseases; Humans; Intra-Abdominal Fat; Obesity; Patient Selection; Piperidines; Pyrazoles; Randomized Controlled Trials as Topic; Receptor, Cannabinoid, CB1; Rimonabant; Risk Assessment; Treatment Outcome	2008
[Residual risk in cardiovascular prevention]. Giornale italiano di cardiologia (2006), 2008, Volume: 9, Issue:4 Suppl 1 Topics: Atherosclerosis; Blood Pressure; Body Weight; Cannabinoid Receptor Antagonists; Cannabinoids; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Follow-Up Studies; Humans; Hypolipidemic Agents; Kaplan-Meier Estimate; Piperidines; Pyrazoles; Randomized Controlled Trials as Topic; Rimonabant; Risk Factors; Smoking Cessation; Thiazolidines; Time Factors	2008
[Dyslipidemia in visceral obesity: pathophysiological mechanisms, clinical implications and therapy]. Giornale italiano di cardiologia (2006), 2008, Volume: 9, Issue:4 Suppl 1 Topics: Atherosclerosis; Bradykinin; Cannabinoid Receptor Antagonists; Cannabinoids; Cardiovascular Diseases; Cholesterol, HDL; Clofibric Acid; Dyslipidemias; Female; Humans; Hypolipidemic Agents; Lipoproteins, HDL; Lipoproteins, LDL; Male; Meta-Analysis as Topic; Obesity; Piperidines; Prospective Studies; Pyrazoles; Randomized Controlled Trials as Topic; Rimonabant; Sex Factors	2008
[Rimonabant helps in overweight patients with multiple cardiovascular risk factors such as type 2 diabetes]. Revue medicale suisse, 2008, Aug-27, Volume: 4, Issue:168 Topics: Cannabinoid Receptor Antagonists; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Overweight; Piperidines; Pyrazoles; Rimonabant	2008
[Nutrition-obesity. Rimonabant and cardiovascular risk factors]. Revue medicale suisse, 2009, Jan-07, Volume: 5, Issue:185 Topics: Anti-Obesity Agents; Cardiovascular Diseases; Humans; Obesity; Piperidines; Pyrazoles; Rimonabant; Risk Factors	2009
Rimonabant: obituary for a wonder drug. Lancet (London, England), 2010, Aug-14, Volume: 376, Issue:9740 Topics: Cannabinoid Receptor Antagonists; Cardiovascular Diseases; Humans; Obesity; Piperidines; Pyrazoles; Rimonabant	2010
Termination of the CRESCENDO trial. Lancet (London, England), 2010, Dec-11, Volume: 376, Issue:9757 Topics: Anti-Obesity Agents; Cardiovascular Agents; Cardiovascular Diseases; Depressive Disorder; Drug Approval; Europe; Humans; Multicenter Studies as Topic; Piperidines; Pyrazoles; Randomized Controlled Trials as Topic; Rimonabant; Suicide; Treatment Failure	2010
Termination of the CRESCENDO trial. Lancet (London, England), 2010, Dec-11, Volume: 376, Issue:9757 Topics: Anti-Obesity Agents; Cardiovascular Agents; Cardiovascular Diseases; Cytochrome P-450 CYP2D6; Depressive Disorder; Europe; Humans; Multicenter Studies as Topic; Piperidines; Pyrazoles; Randomized Controlled Trials as Topic; Research Design; Rimonabant; Suicide; Treatment Failure	2010
[Long-term effects of weight-reducing drugs in hypertensive patients--a survey of a Cochrane review]. Ugeskrift for laeger, 2011, Feb-21, Volume: 173, Issue:8 Topics: Adult; Anti-Obesity Agents; Appetite Depressants; Blood Pressure; Cardiovascular Diseases; Cyclobutanes; Evidence-Based Medicine; Humans; Hypertension; Lactones; Obesity; Orlistat; Piperidines; Pyrazoles; Randomized Controlled Trials as Topic; Rimonabant; Time Factors; Treatment Outcome; Weight Loss	2011
Retinol-binding protein 4 : a possible role in cardiovascular complications. British journal of pharmacology, 2011, Volume: 164, Issue:8 Topics: 3T3-L1 Cells; Adipokines; Animals; Apolipoprotein E3; Atherosclerosis; Base Sequence; Cardiovascular Diseases; Cholesterol; DNA Primers; Female; Gene Expression Regulation; Hypercholesterolemia; Inflammation; Mice; Mice, Inbred C57BL; Obesity; Piperidines; Pyrazoles; Real-Time Polymerase Chain Reaction; Retinol-Binding Proteins, Plasma; Rimonabant	2011
[Blocking the endocannabinoid system -- weight reduction and cardiovascular risk management]. Deutsche medizinische Wochenschrift (1946), 2005, Mar-24, Volume: 130, Issue:12 Topics: Cannabinoid Receptor Modulators; Cardiovascular Diseases; Clinical Trials as Topic; Endocannabinoids; Humans; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Rimonabant; Risk Factors; Treatment Outcome; Weight Loss	2005
[Highlights from the American College of Cardiology Annual Scientific Session 2005: March 5-9, 2005, Orlando, Florida]. Revue medicale suisse, 2005, May-04, Volume: 1, Issue:18 Topics: Aspirin; Cardiovascular Diseases; Cholesterol, LDL; Clopidogrel; Humans; Hypercholesterolemia; Obesity; Piperidines; Platelet Aggregation Inhibitors; Pyrazoles; Rimonabant; Stroke; Ticlopidine	2005
[Reducing obesity]. Presse medicale (Paris, France : 1983), 2006, Volume: 35, Issue:1 Pt 1 Topics: Adolescent; Adult; Appetite Depressants; Body Mass Index; Cardiovascular Diseases; Child; Cyclobutanes; Female; Humans; Life Style; Male; Middle Aged; Obesity; Piperidines; Pyrazoles; Randomized Controlled Trials as Topic; Rimonabant; Risk Factors; Surveys and Questionnaires; Weight Loss	2006
Metabolic risk factors, drugs, and obesity. The New England journal of medicine, 2006, Mar-02, Volume: 354, Issue:9 Topics: Anti-Obesity Agents; Cardiovascular Diseases; Dyslipidemias; Glucose Intolerance; Humans; Obesity; Overweight; Piperidines; Pyrazoles; Rimonabant; Weight Loss	2006
Optimal treatments for the metabolic syndrome. Arteriosclerosis, thrombosis, and vascular biology, 2006, Volume: 26, Issue:4 Topics: Anti-Obesity Agents; Cardiovascular Diseases; Complementary Therapies; Diabetes Mellitus; Diet; Health Behavior; Humans; Hypoglycemic Agents; Life Style; Metabolic Syndrome; Metformin; Obesity; Piperidines; Pyrazoles; Randomized Controlled Trials as Topic; Rimonabant; Rosiglitazone; Thiazolidinediones	2006
Update on rimonabant--a selective cannabinoid CB1 antagonist. The Annals of pharmacotherapy, 2006, Volume: 40, Issue:5 Topics: Cardiovascular Diseases; Dyslipidemias; Humans; Obesity; Piperidines; Pyrazoles; Randomized Controlled Trials as Topic; Receptor, Cannabinoid, CB1; Rimonabant; Risk Factors	2006
[Cardiac metabolic risk factors. CB1-blocker corrects three with one stroke]. MMW Fortschritte der Medizin, 2006, Aug-31, Volume: 148, Issue:35-36 Topics: Adolescent; Adult; Age Factors; Aged; Blood Glucose; Body Mass Index; Cardiovascular Diseases; Cholesterol, HDL; Clinical Trials, Phase III as Topic; Contraindications; Diabetes Mellitus, Type 2; Female; Glycated Hemoglobin; Humans; Male; Middle Aged; Obesity; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Rimonabant; Risk Factors; Time Factors; Triglycerides; Weight Loss	2006
[Rimonabant actions on cardiometabolic risk factors]. Medizinische Monatsschrift fur Pharmazeuten, 2007, Volume: 30, Issue:1 Topics: Cardiovascular Diseases; Humans; Metabolic Syndrome; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Rimonabant; Risk Factors	2007
Cardiometabolic risk modification: current trends and emerging therapies. JAAPA : official journal of the American Academy of Physician Assistants, 2006, Volume: Suppl Cardiometabolic Topics: Adipose Tissue; Antihypertensive Agents; Appetite; Body Weight; C-Reactive Protein; Cannabinoid Receptor Modulators; Cardiovascular Diseases; Cholesterol, HDL; Diabetes Mellitus; Humans; Hypoglycemic Agents; Life Style; Metabolic Syndrome; Obesity; Physician Assistants; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Rimonabant; Risk Assessment; Risk Factors; Weight Gain	2006
A call to action: new treatment options provide even more reasons to intervene in tobacco dependence. Nature clinical practice. Cardiovascular medicine, 2007, Volume: 4, Issue:9 Topics: Benzazepines; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Dyslipidemias; Humans; Obesity; Piperidines; Prevalence; Pyrazoles; Quinoxalines; Rimonabant; Risk Factors; Smoking; Smoking Cessation; Tobacco Use Disorder; Varenicline	2007
Management of obesity in patients with peripheral arterial disease. European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery, 2007, Volume: 34, Issue:5 Topics: Anti-Obesity Agents; Bariatric Surgery; Body Composition; Body Mass Index; Cannabinoid Receptor Antagonists; Cardiovascular Diseases; Humans; Life Style; Obesity; Peripheral Vascular Diseases; Piperidines; Pyrazoles; Rimonabant; Risk Factors; Tomography, X-Ray Computed	2007
[New drugs; rimonabant]. Nederlands tijdschrift voor geneeskunde, 2007, Nov-24, Volume: 151, Issue:47 Topics: Appetite Regulation; Cardiovascular Diseases; Depression; Diet, Reducing; Energy Intake; Humans; Lipids; Lipogenesis; Obesity; Obesity, Morbid; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Rimonabant; Weight Loss	2007
Efficacy and safety of rimonabant for improvement of multiple cardiometabolic risk factors in overweight/obese patients: pooled 1-year data from the Rimonabant in Obesity (RIO) program. Diabetes care, 2008, Volume: 31 Suppl 2 Topics: Cannabinoid Receptor Antagonists; Cannabinoids; Cardiovascular Diseases; Clinical Trials, Phase III as Topic; Diet, Reducing; Exercise; Heart Diseases; Humans; Metabolic Diseases; Obesity; Overweight; Piperidines; Pyrazoles; Rimonabant; Risk Factors; Safety	2008
Cardiovascular effects of 2-arachidonoyl glycerol in anesthetized mice. Hypertension (Dallas, Tex. : 1979), 2000, Volume: 35, Issue:2 Topics: Anesthesia; Animals; Arachidonic Acids; Blood Pressure; Camphanes; Cardiovascular Agents; Cardiovascular Diseases; Dose-Response Relationship, Drug; Endocannabinoids; Female; Glycerides; Heart Rate; Hypotension; Indomethacin; Ligands; Male; Mice; Mice, Inbred ICR; Mice, Knockout; Piperidines; Pyrazoles; Receptors, Cannabinoid; Receptors, Drug; Rimonabant; Tachycardia	2000